Floatz logo

Piritramide

Circulating Tumor Cell

The Institute of Molecular and Translational Medicine, Czech RepublicSmall moleculePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Circulating Tumor Cell cohort.

Asset / SponsorPhaseRating
NEPENTHE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
Capecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
AC Camargo Cancer Center
Phase 2CCC
TRASTUZUMAB
AC Camargo Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Piritramide is also rated in:

Minimal Residual DiseaseDormant
B
Indicative ·
62 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
59 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →